InnoCare Pharma has received approval from the China National Medical Products Administration to conduct clinical trials for ICP-538, a VAV1-directed molecular glue degrader for autoimmune diseases. This is the first VAV1 degrader approved in China and second globally, offering a new treatment option for conditions like inflammatory bowel disease and multiple sclerosis. The drug targets VAV1 protein to inhibit T-cell and B-cell activation, showing promising results in preclinical studies. InnoCare CEO Dr. Jasmine Cui believes this novel therapy could provide high target selectivity and efficacy for patients with autoimmune diseases.

Read more at GlobeNewswire: InnoCare Announces IND Approval to Initiate Clinical Trial